Agendia Introduces New Breast Cancer Recurrence Test BluePrint
The new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors. MammaPrint is the breast cancer recurrence
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.